Wanbangde Pharmaceutical Group Co., Ltd. Announces Public Disclosure of the Environmental Impact Assessment for Its New Technical Renovation Project, which will add annual production capacity for 20 tons of Bifendate API, 980 tons of Norfloxacin API, and 10 tons of Traditional Chinese Medicine Extracts.

Home

About Us

• Company Profile

• HIstory

• Culture

• Honor

Products

• Cardiovascular series

• Psychiatry series

• Hepatobiliary, Gastroenterology Series

• Respiratory series

• Anti-infective virus series

• Other series

• Large Infusion Series

• Huabao Tong Series

• Active Pharmaceutical Ingredient Series

R&D

• Academician Expert Workstation

• Medical Research and Industry Alliance

News

• General News

• Party group dynamics

• Employee activity

HR

• Talent Strategy

• Company recruitment

Contact us

中文版